Corient Private Wealth
CRNX

Corient Private Wealth’s Crinetics Pharmaceuticals CRNX Stock Holding History

Corient Private Wealth’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,564
Closed -$672K – 3080
2026
Q1 		$672K Buy
+18,564
New +$829K ﹤0.01% 1870

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's CRNX Position: Q2 2026 in Review

Corient Private Wealth sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 18,564 shares — an estimated $672K sold.

Corient Private Wealth first reported a position in CRNX in Q1 2026 and held it in 1 quarter. The position peaked at $672K in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Corient Private Wealth reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Corient Private Wealth sold 18,564 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $672K.
  • Corient Private Wealth first reported a position in Crinetics Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Corient Private Wealth's Crinetics Pharmaceuticals position peaked at $672K in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.